JPWO2022202816A1 - - Google Patents
Info
- Publication number
- JPWO2022202816A1 JPWO2022202816A1 JP2023509199A JP2023509199A JPWO2022202816A1 JP WO2022202816 A1 JPWO2022202816 A1 JP WO2022202816A1 JP 2023509199 A JP2023509199 A JP 2023509199A JP 2023509199 A JP2023509199 A JP 2023509199A JP WO2022202816 A1 JPWO2022202816 A1 JP WO2022202816A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021047773 | 2021-03-22 | ||
| JP2021192510 | 2021-11-26 | ||
| PCT/JP2022/013180 WO2022202816A1 (ja) | 2021-03-22 | 2022-03-22 | ペプチド及びペプチドを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022202816A1 true JPWO2022202816A1 (https=) | 2022-09-29 |
| JPWO2022202816A5 JPWO2022202816A5 (https=) | 2025-04-03 |
Family
ID=83395638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509199A Pending JPWO2022202816A1 (https=) | 2021-03-22 | 2022-03-22 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240209027A1 (https=) |
| EP (1) | EP4317174A4 (https=) |
| JP (1) | JPWO2022202816A1 (https=) |
| KR (1) | KR20230170918A (https=) |
| AU (1) | AU2022242421A1 (https=) |
| BR (1) | BR112023019228A2 (https=) |
| CA (1) | CA3214455A1 (https=) |
| IL (1) | IL307225A (https=) |
| MX (1) | MX2023011194A (https=) |
| TW (1) | TW202304947A (https=) |
| WO (1) | WO2022202816A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023048151A1 (ja) * | 2021-09-22 | 2023-03-30 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する環状ペプチド |
| US20250250299A1 (en) * | 2022-03-28 | 2025-08-07 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| CN116445523B (zh) * | 2023-04-10 | 2024-05-07 | 西北农林科技大学 | 一种小麦抗逆性基因TaBSL3与应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008531485A (ja) * | 2005-02-17 | 2008-08-14 | ポリファー リミテッド | プロテアーゼ阻害活性を有するテンプレート固定β−ヘアピンペプチド擬似体 |
| JP2012058092A (ja) * | 2010-09-09 | 2012-03-22 | Univ Of Tokyo | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| CN111349150A (zh) * | 2020-03-24 | 2020-06-30 | 北京中科微盾生物科技有限责任公司 | 一种抑制新型冠状病毒的多肽及其用途 |
| CN111471088A (zh) * | 2020-04-21 | 2020-07-31 | 北京中科微盾生物科技有限责任公司 | 一种抑制sars-cov-2感染的多肽、组合物及其用途 |
| CN111499692A (zh) * | 2020-06-16 | 2020-08-07 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
| CN111732637A (zh) * | 2020-05-25 | 2020-10-02 | 上海交通大学 | 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用 |
| CN112630444A (zh) * | 2020-12-11 | 2021-04-09 | 珠海碳云智能科技有限公司 | 基于靶点蛋白的多肽筛选方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| WO2007066627A1 (ja) | 2005-12-06 | 2007-06-14 | The University Of Tokyo | 多目的アシル化触媒とその用途 |
| US20160068835A1 (en) | 2013-01-30 | 2016-03-10 | Peptidream Inc. | Flexible display method |
| CN111643656B (zh) * | 2020-05-14 | 2022-07-19 | 悦康药业集团股份有限公司 | 广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用 |
-
2022
- 2022-03-22 WO PCT/JP2022/013180 patent/WO2022202816A1/ja not_active Ceased
- 2022-03-22 TW TW111110690A patent/TW202304947A/zh unknown
- 2022-03-22 AU AU2022242421A patent/AU2022242421A1/en active Pending
- 2022-03-22 IL IL307225A patent/IL307225A/en unknown
- 2022-03-22 JP JP2023509199A patent/JPWO2022202816A1/ja active Pending
- 2022-03-22 EP EP22775599.8A patent/EP4317174A4/en active Pending
- 2022-03-22 MX MX2023011194A patent/MX2023011194A/es unknown
- 2022-03-22 US US18/283,376 patent/US20240209027A1/en active Pending
- 2022-03-22 BR BR112023019228A patent/BR112023019228A2/pt not_active Application Discontinuation
- 2022-03-22 KR KR1020237035941A patent/KR20230170918A/ko active Pending
- 2022-03-22 CA CA3214455A patent/CA3214455A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008531485A (ja) * | 2005-02-17 | 2008-08-14 | ポリファー リミテッド | プロテアーゼ阻害活性を有するテンプレート固定β−ヘアピンペプチド擬似体 |
| JP2012058092A (ja) * | 2010-09-09 | 2012-03-22 | Univ Of Tokyo | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| CN111349150A (zh) * | 2020-03-24 | 2020-06-30 | 北京中科微盾生物科技有限责任公司 | 一种抑制新型冠状病毒的多肽及其用途 |
| CN111471088A (zh) * | 2020-04-21 | 2020-07-31 | 北京中科微盾生物科技有限责任公司 | 一种抑制sars-cov-2感染的多肽、组合物及其用途 |
| CN111732637A (zh) * | 2020-05-25 | 2020-10-02 | 上海交通大学 | 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用 |
| CN111499692A (zh) * | 2020-06-16 | 2020-08-07 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
| CN112630444A (zh) * | 2020-12-11 | 2021-04-09 | 珠海碳云智能科技有限公司 | 基于靶点蛋白的多肽筛选方法 |
Non-Patent Citations (1)
| Title |
|---|
| BRUST, ANDREAS ET AL., J. MED. CHEM., vol. 59, JPN6022022014, 2016, pages 2381 - 2395, ISSN: 0005804868 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4317174A4 (en) | 2025-04-02 |
| BR112023019228A2 (pt) | 2023-11-28 |
| KR20230170918A (ko) | 2023-12-19 |
| WO2022202816A1 (ja) | 2022-09-29 |
| TW202304947A (zh) | 2023-02-01 |
| US20240209027A1 (en) | 2024-06-27 |
| EP4317174A1 (en) | 2024-02-07 |
| CA3214455A1 (en) | 2022-09-29 |
| AU2022242421A2 (en) | 2023-11-16 |
| AU2022242421A1 (en) | 2023-11-02 |
| MX2023011194A (es) | 2024-01-04 |
| IL307225A (en) | 2023-11-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250324 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250324 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20251107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260427 |